Related Experiment Videos
Postgonococcal urethritis: a double-blind study of doxycycline vs placebo
K A Mclean1, B A Evans, J M Lim
1Department of Genitourinary Medicine and Medical Microbiology, West London, UK.
Genitourinary Medicine
|February 1, 1990
Summary
Adding doxycycline to gonorrhea treatment significantly reduced postgonococcal urethritis (PGU) incidence. This study investigated PGU occurrence in men receiving doxycycline or placebo alongside standard gonorrhea care.
Area of Science:
- Urology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Postgonococcal urethritis (PGU) is a common complication following treatment for gonorrhea.
- The etiology of PGU is not fully understood, but Chlamydia trachomatis and Mycoplasma hominis are implicated.
- Effective prevention strategies for PGU are needed.
Purpose of the Study:
- To evaluate the efficacy of oral doxycycline in preventing postgonococcal urethritis (PGU) in heterosexual men.
- To assess the role of persistent chlamydial infection and other microorganisms in PGU development.
Main Methods:
- A randomized controlled trial involving 216 heterosexual men treated for urethral gonorrhea.
- Participants received either a 7-day course of oral doxycycline or a placebo, in addition to standard single-dose treatment.
- Patients were assessed for PGU development and presence of microbial infections at follow-up.
Main Results:
- The incidence of PGU was significantly lower in the doxycycline group (26.8%) compared to the placebo group (51.9%) (p < 0.001).
- Symptomatic PGU was infrequent in both groups.
- Persistent Chlamydia trachomatis infection was associated with PGU development in the placebo group.
Conclusions:
- A 7-day course of oral doxycycline is effective in reducing the incidence of postgonococcal urethritis (PGU) in men treated for gonorrhea.
- While doxycycline reduces PGU, a significant proportion of cases remain with unknown etiology.
- Further research is needed to elucidate the remaining causes of PGU.